Cargando…

Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma

Clear cell renal cell carcinoma (ccRCC), the most common subtype, accounts for approximately 80% of all RCC cases. ccRCC patients typically present with an advanced stage at the time of diagnosis resulting in a poor patient prognosis. The present study aimed to identify novel potential microRNAs (mi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Siming, Deng, Xiaojun, Zhang, Jiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854552/
https://www.ncbi.nlm.nih.gov/pubmed/31661117
http://dx.doi.org/10.3892/mmr.2019.10762
_version_ 1783470229760770048
author Liu, Siming
Deng, Xiaojun
Zhang, Jiong
author_facet Liu, Siming
Deng, Xiaojun
Zhang, Jiong
author_sort Liu, Siming
collection PubMed
description Clear cell renal cell carcinoma (ccRCC), the most common subtype, accounts for approximately 80% of all RCC cases. ccRCC patients typically present with an advanced stage at the time of diagnosis resulting in a poor patient prognosis. The present study aimed to identify novel potential microRNAs (miRNAs or miRs) in peripheral blood as biomarkers for the detection of ccRCC. Candidate miRNAs were selected through integrated analysis of the Gene Expression Omnibus (GEO) database, The Cancer Genome Atlas (TCGA) database, and from clinical samples. The expression levels of miRNAs were quantified using reverse transcription-quantitative PCR. Receiver operating characteristic (ROC) curve analysis was used to explore the diagnostic values of the miRNAs. Bioinformatic analysis of candidate miRNAs was conducted by using the STRING database. After an integrated analysis of the GEO and TCGA databases, four miRNAs were found to be consistently dysregulated in ccRCC tissues. Then, their expression levels in serum and diagnostic utilities were further explored. We discovered that serum miR-508-3p and miR-885-5p were significantly dysregulated in ccRCC patients with marked diagnostic values. The area under the ROC curve (AUC) of serum miR-508-3p and miR-885-5p was 0.80 (95% CI, 0.73–0.87) and 0.87 (95% CI, 0.79–0.95), respectively. Functional enrichment analysis revealed that both miR-508-3p and miR-885-5p were closely associated with cellular metabolic processes. In conclusion, serum miR-508-3p and miR-885-5p are novel potential biomarkers for the diagnosis of ccRCC.
format Online
Article
Text
id pubmed-6854552
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-68545522019-11-21 Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma Liu, Siming Deng, Xiaojun Zhang, Jiong Mol Med Rep Articles Clear cell renal cell carcinoma (ccRCC), the most common subtype, accounts for approximately 80% of all RCC cases. ccRCC patients typically present with an advanced stage at the time of diagnosis resulting in a poor patient prognosis. The present study aimed to identify novel potential microRNAs (miRNAs or miRs) in peripheral blood as biomarkers for the detection of ccRCC. Candidate miRNAs were selected through integrated analysis of the Gene Expression Omnibus (GEO) database, The Cancer Genome Atlas (TCGA) database, and from clinical samples. The expression levels of miRNAs were quantified using reverse transcription-quantitative PCR. Receiver operating characteristic (ROC) curve analysis was used to explore the diagnostic values of the miRNAs. Bioinformatic analysis of candidate miRNAs was conducted by using the STRING database. After an integrated analysis of the GEO and TCGA databases, four miRNAs were found to be consistently dysregulated in ccRCC tissues. Then, their expression levels in serum and diagnostic utilities were further explored. We discovered that serum miR-508-3p and miR-885-5p were significantly dysregulated in ccRCC patients with marked diagnostic values. The area under the ROC curve (AUC) of serum miR-508-3p and miR-885-5p was 0.80 (95% CI, 0.73–0.87) and 0.87 (95% CI, 0.79–0.95), respectively. Functional enrichment analysis revealed that both miR-508-3p and miR-885-5p were closely associated with cellular metabolic processes. In conclusion, serum miR-508-3p and miR-885-5p are novel potential biomarkers for the diagnosis of ccRCC. D.A. Spandidos 2019-12 2019-10-22 /pmc/articles/PMC6854552/ /pubmed/31661117 http://dx.doi.org/10.3892/mmr.2019.10762 Text en Copyright: © Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Liu, Siming
Deng, Xiaojun
Zhang, Jiong
Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma
title Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma
title_full Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma
title_fullStr Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma
title_full_unstemmed Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma
title_short Identification of dysregulated serum miR-508-3p and miR-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma
title_sort identification of dysregulated serum mir-508-3p and mir-885-5p as potential diagnostic biomarkers of clear cell renal carcinoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854552/
https://www.ncbi.nlm.nih.gov/pubmed/31661117
http://dx.doi.org/10.3892/mmr.2019.10762
work_keys_str_mv AT liusiming identificationofdysregulatedserummir5083pandmir8855paspotentialdiagnosticbiomarkersofclearcellrenalcarcinoma
AT dengxiaojun identificationofdysregulatedserummir5083pandmir8855paspotentialdiagnosticbiomarkersofclearcellrenalcarcinoma
AT zhangjiong identificationofdysregulatedserummir5083pandmir8855paspotentialdiagnosticbiomarkersofclearcellrenalcarcinoma